Children ' s Cancer Group lymphoblastic leukemia : a combined analysis of prognostic markers Risk-and response-based classification of childhood B-precursor acute

Bruce M. Camitta Elizabeth A. Raetz, Naomi J. Winick, Stephen P. Hunger, William L. Carroll, Paul S. Gaynon and Michael J. Borowitz, Andrew J. Carroll, Nyla A. Heerema, Jeffrey E. Rubnitz, Mignon L. Loh, Kirk R. Schultz, D. Jeanette Pullen, Harland N. Sather, Jonathan J. Shuster, Meenakshi Devidas, (CCG) from the Pediatric Oncology Group (POG) and Children's Cancer Group lymphoblastic leukemia: a combined analysis of prognostic markers Riskand response-based classification of childhood B-precursor acute

[1]  L. Frankel,et al.  Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[3]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[4]  N. Heerema,et al.  Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Haber,et al.  Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Pui,et al.  The eighth international childhood acute lymphoblastic leukemia workshop (‘Ponte di Legno meeting’) report: Vienna, Austria, April 27–28, 2005 , 2006, Leukemia.

[7]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[8]  J. Neglia,et al.  A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. , 2002, Blood.

[9]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Richard Aplenc,et al.  Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia , 2004, British journal of haematology.

[11]  J. Shuster,et al.  Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986–1994 , 2000, Leukemia.

[12]  H. Sather,et al.  Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D C Ward,et al.  Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  N. Heerema,et al.  Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group , 2004, Leukemia.

[15]  W. Bleyer,et al.  Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995 , 2000, Leukemia.

[16]  A. Look,et al.  Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. , 1992, Blood.

[17]  B. Camitta,et al.  Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Winick,et al.  Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Pui,et al.  Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements , 2003, Leukemia.

[20]  G. M. Taylor,et al.  Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. J,et al.  Rearrangement of the MLL Gene Confers a Poor Prognosis in Childhood Acute Lymphoblastic Leukemia , Regardless of Presenting Age , 2002 .

[22]  W. Carroll,et al.  Individualized therapy for childhood acute lymphoblastic leukemia. , 2005, Personalized medicine.

[23]  M. Schrappe,et al.  Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study , 2005, The Lancet.

[24]  N. Heerema,et al.  Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Baruchel,et al.  Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE) , 2000, British Journal of Cancer.

[26]  H. Sather,et al.  Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  N. Heerema,et al.  Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2003, Blood.

[28]  M. Schrappe.  Evolution of BFM trials for childhood ALL. , 2004, Annals of hematology.

[29]  S. Hunger,et al.  Childhood leukemia--new advances and challenges. , 2004, The New England journal of medicine.

[30]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[31]  C. Pui,et al.  Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2000, The New England journal of medicine.

[32]  F. Behm,et al.  Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. , 1990, Blood.

[33]  D. Le Paslier,et al.  The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. , 1995, Blood.

[34]  H. Sather,et al.  Early response to therapy and outcome in childhood acute lymphoblastic leukemia , 1997, Cancer.

[35]  M. Bleakley,et al.  Allogeneic bone marrow transplantation for childhood relapsed acute lymphoblastic leukemia: comparison of outcome in patients with and without a matched family donor , 2002, Bone Marrow Transplantation.

[36]  N. Winick,et al.  A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial , 2001, Leukemia.

[37]  N. Heerema,et al.  Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P S Gaynon,et al.  Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Schrappe,et al.  Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. , 2005, JAMA.

[40]  G. Leverger,et al.  Francaise d ' Oncologie Pediatrique LMB 89 protocol : highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L 3 leukemia , 2001 .